Skip to main content
Premium Trial:

Request an Annual Quote

Array BioPharma to Use Horizon Discovery's X-MAN Lines

NEW YORK (GenomeWeb News) – Horizon Discovery said today that Array BioPharma will use its X-MAN human isogenic cell lines to evaluate a target that could be used as a cancer treatment.

Array will evaluate a panel of the X-MAN cell lines carrying specific mutant cancer genes with matched parental genetic backgrounds. Array aims to study the potential utility of its compounds and will share some of the data it generates over the course of the evaluation period, which starts this month.

"We are rapidly getting our novel 'patient-relevant' X-MAN cancer models into real world drug discovery research programs," Darrin Disley, Horizon's chairman and commercial director, said in a statement.

Financial terms of the agreement were not released.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.